These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38287659)

  • 21. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM
    J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
    Kister I; Patskovsky Y; Curtin R; Pei J; Perdomo K; Rimler Z; Voloshyna I; Samanovic MI; Cornelius AR; Velmurugu Y; Nyovanie S; Kim JJ; Tardio E; Bacon TE; Zhovtis Ryerson L; Raut P; Pedotti R; Hawker K; Raposo C; Priest J; Cabatingan M; Winger RC; Mulligan MJ; Krogsgaard M; Silverman GJ
    Ann Neurol; 2022 Jun; 91(6):782-795. PubMed ID: 35289960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy.
    Bilge N; Kesmez Can F; Yevgi R
    Acta Neurol Belg; 2023 Oct; 123(5):1885-1892. PubMed ID: 36331727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
    Zabalza A; Cárdenas-Robledo S; Tagliani P; Arrambide G; Otero-Romero S; Carbonell-Mirabent P; Rodriguez-Barranco M; Rodríguez-Acevedo B; Restrepo Vera JL; Resina-Salles M; Midaglia L; Vidal-Jordana A; Río J; Galan I; Castillo J; Cobo-Calvo Á; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
    Eur J Neurol; 2021 Oct; 28(10):3384-3395. PubMed ID: 33340215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.
    Mantero V; Abate L; Balgera R; Basilico P; Salmaggi A; Cordano C
    Mult Scler Relat Disord; 2020 Nov; 46():102453. PubMed ID: 32835900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
    Garjani A; Patel S; Bharkhada D; Rashid W; Coles A; Law GR; Evangelou N
    Mult Scler Relat Disord; 2022 Jan; 57():103458. PubMed ID: 34896876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
    Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K
    Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation.
    Mariottini A; Lotti A; Innocenti C; Repice AM; Nozzoli C; Boncompagni R; Fainardi E; Saccardi R; Massacesi L
    Eur J Neurol; 2023 Oct; 30(10):3362-3366. PubMed ID: 37483174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection.
    Bigaut K; Kremer L; Fleury M; Lanotte L; Collongues N; de Seze J
    Rev Neurol (Paris); 2021 Dec; 177(10):1237-1240. PubMed ID: 34172292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Outcome of COVID-19 in Pediatric-Onset Multiple Sclerosis Patients.
    Oncel I; Alici N; Solmaz I; Oge DD; Ozsurekci Y; Anlar B
    Pediatr Neurol; 2022 Sep; 134():7-10. PubMed ID: 35772229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The presence of SARS-CoV2 antibodies in MS patients.
    Wallach AI; Picone MA
    Mult Scler Relat Disord; 2021 May; 50():102793. PubMed ID: 33588315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
    Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of multiple sclerosis patients admitted with COVID-19 in a large veteran cohort.
    Fuchs TA; Wattengel BA; Carter MT; El-Solh AA; Lesse AJ; Mergenhagen KA
    Mult Scler Relat Disord; 2022 Aug; 64():103964. PubMed ID: 35724529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
    Schiavetti I; Cordioli C; Stromillo ML; Teresa Ferrò M; Laroni A; Cocco E; Cola G; Pasquali L; Rilla MT; Signoriello E; Iodice R; Di Sapio A; Lanzillo R; Caleri F; Annovazzi P; Conte A; Liberatore G; Ruscica F; Docimo R; Bonavita S; Ulivelli M; Cavalla P; Patti F; Ferraro D; Clerico M; Immovilli P; Di Filippo M; Salvetti M; Sormani MP
    Mult Scler; 2022 Nov; 28(13):2106-2111. PubMed ID: 35735030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
    Sancho-Saldaña A; Gil-Sánchez A; González-Mingot C; Peralta S; Solana MJ; Torres P; Juanes A; Quibus L; Ruiz E; Sanpedro E; Quirant-Sánchez B; Martínez-Cáceres E; Ramo Tello C; Presas-Rodríguez S; García Rubio S; Baron BP; Ramió-Torrentà L; Sotoca J; González-Suárez I; Eichau S; Prieto-González JM; Blasco Quilez MR; Sabín-Muñoz J; Sánchez-López AJ; Llorens Calatayud G; Calles C; Sempere ÁP; Garcés M; Carmona O; Moral E; Hervás JV; Blanco Y; Sola-Valls N; Tellez Lara N; Forero L; Brieva L
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review.
    Bazylewicz M; Gudowska-Sawczuk M; Mroczko B; Kochanowicz J; Kułakowska A
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
    Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
    Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC).
    Klineova S; Harel A; Straus Farber R; DeAngelis T; Zhang Y; Hentz R; Leung TM; Fong K; Smith T; Blanck R; Zhovtis-Ryerson L
    Mult Scler Relat Disord; 2021 Oct; 55():103153. PubMed ID: 34392059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis.
    Jacober SLS; Disanto G; Sacco R; Meng D; Mallucci G; Candrian U; Semini S; Tiberti M; Gobbi C; Zecca C
    Mult Scler; 2023 Dec; 29(14):1765-1775. PubMed ID: 37786964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.